Literature DB >> 29801093

Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses: A Systematic Review.

David S Fink1, Julia P Schleimer1, Aaron Sarvet1, Kiran K Grover1, Chris Delcher2, Alvaro Castillo-Carniglia3, June H Kim4, Ariadne E Rivera-Aguirre3, Stephen G Henry3, Silvia S Martins1, Magdalena Cerdá3.   

Abstract

Background: Prescription drug monitoring programs (PDMPs) are a key component of the president's Prescription Drug Abuse Prevention Plan to prevent opioid overdoses in the United States. Purpose: To examine whether PDMP implementation is associated with changes in nonfatal and fatal overdoses; identify features of programs differentially associated with those outcomes; and investigate any potential unintended consequences of the programs. Data Sources: Eligible publications from MEDLINE, Current Contents Connect (Clarivate Analytics), Science Citation Index (Clarivate Analytics), Social Sciences Citation Index (Clarivate Analytics), and ProQuest Dissertations indexed through 27 December 2017 and additional studies from reference lists. Study Selection: Observational studies (published in English) from U.S. states that examined an association between PDMP implementation and nonfatal or fatal overdoses. Data Extraction: 2 investigators independently extracted data from and rated the risk of bias (ROB) of studies by using established criteria. Consensus determinations involving all investigators were used to grade strength of evidence for each intervention. Data Synthesis: Of 2661 records, 17 articles met the inclusion criteria. These articles examined PDMP implementation only (n = 8), program features only (n = 2), PDMP implementation and program features (n = 5), PDMP implementation with mandated provider review combined with pain clinic laws (n = 1), and PDMP robustness (n = 1). Evidence from 3 studies was insufficient to draw conclusions regarding an association between PDMP implementation and nonfatal overdoses. Low-strength evidence from 10 studies suggested a reduction in fatal overdoses with PDMP implementation. Program features associated with a decrease in overdose deaths included mandatory provider review, provider authorization to access PDMP data, frequency of reports, and monitoring of nonscheduled drugs. Three of 6 studies found an increase in heroin overdoses after PDMP implementation. Limitation: Few studies, high ROB, and heterogeneous analytic methods and outcome measurement.
Conclusion: Evidence that PDMP implementation either increases or decreases nonfatal or fatal overdoses is largely insufficient, as is evidence regarding positive associations between specific administrative features and successful programs. Some evidence showed unintended consequences. Research is needed to identify a set of "best practices" and complementary initiatives to address these consequences. Primary Funding Source: National Institute on Drug Abuse and Bureau of Justice Assistance.

Entities:  

Mesh:

Year:  2018        PMID: 29801093      PMCID: PMC6015770          DOI: 10.7326/M17-3074

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  33 in total

1.  Drug Overdose Deaths in the United States, 1999-2016.

Authors:  Holly Hedegaard; Margaret Warner; Arialdi M Miniño
Journal:  NCHS Data Brief       Date:  2017-12

2.  Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings.

Authors:  N J Pauly; S Slavova; C Delcher; P R Freeman; J Talbert
Journal:  Drug Alcohol Depend       Date:  2018-01-11       Impact factor: 4.492

3.  State prescription drug monitoring programs and fatal drug overdoses.

Authors:  Young Hee Nam; Dennis G Shea; Yunfeng Shi; John R Moran
Journal:  Am J Manag Care       Date:  2017-05       Impact factor: 2.229

4.  Reductions in prescription opioid diversion following recent legislative interventions in Florida.

Authors:  Hilary L Surratt; Catherine O'Grady; Steven P Kurtz; Yamilka Stivers; Theodore J Cicero; Richard C Dart; Minxing Chen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03       Impact factor: 2.890

5.  Prescription and Illicit Opioid Deaths and the Prescription Drug Monitoring Program in Florida.

Authors:  Chris Delcher; Yanning Wang; Alexander C Wagenaar; Bruce A Goldberger; Robert L Cook; Mildred M Maldonado-Molina
Journal:  Am J Public Health       Date:  2016-06       Impact factor: 9.308

6.  Do more robust prescription drug monitoring programs reduce prescription opioid overdose?

Authors:  Bryce Pardo
Journal:  Addiction       Date:  2017-02-08       Impact factor: 6.526

7.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

8.  The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States.

Authors:  Michael Joynt; Meghan K Train; Brett W Robbins; Jill S Halterman; Enrico Caiola; Robert J Fortuna
Journal:  J Gen Intern Med       Date:  2013-12       Impact factor: 5.128

9.  Drug Overdose Deaths in the United States, 1999-2015.

Authors:  Holly Hedegaard; Margaret Warner; Arialdi M Minino
Journal:  NCHS Data Brief       Date:  2017-02

10.  "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting.

Authors:  Sarah G Mars; Philippe Bourgois; George Karandinos; Fernando Montero; Daniel Ciccarone
Journal:  Int J Drug Policy       Date:  2013-10-19
View more
  50 in total

1.  Implementation and enforcement of state opioid prescribing laws.

Authors:  Elizabeth M Stone; Lainie Rutkow; Mark C Bicket; Colleen L Barry; G Caleb Alexander; Emma E McGinty
Journal:  Drug Alcohol Depend       Date:  2020-06-11       Impact factor: 4.492

2.  Opioid Prescribing Laws Are Not Associated with Short-term Declines in Prescription Opioid Distribution.

Authors:  Corey S Davis; Brian J Piper; Alex K Gertner; Jason S Rotter
Journal:  Pain Med       Date:  2020-03-01       Impact factor: 3.750

3.  Impact of a prescription drug monitoring program use mandate on potentially problematic patterns of opioid analgesic prescriptions in New York City.

Authors:  Marcus A Bachhuber; Ellenie Tuazon; Michelle L Nolan; Hillary V Kunins; Denise Paone
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-03-28       Impact factor: 2.890

4.  Prescription Drug Monitoring Programs and Prescription Opioid-Related Outcomes in the United States.

Authors:  Victor Puac-Polanco; Stanford Chihuri; David S Fink; Magdalena Cerdá; Katherine M Keyes; Guohua Li
Journal:  Epidemiol Rev       Date:  2020-01-31       Impact factor: 6.222

5.  Treading the tightrope of opioid restrictions.

Authors:  Michael Eisenstein
Journal:  Nature       Date:  2019-09       Impact factor: 49.962

6.  Opioid e-prescribing trends at discharge in a large pediatric health system.

Authors:  Christopher M Horvat; Brian Martin; Liwen Wu; Anthony Fabio; Phil E Empey; Fanuel Hagos; Sheila Bigelow; Sajel Kantawala; Alicia K Au; Patrick M Kochanek; Robert S B Clark
Journal:  J Opioid Manag       Date:  2019 Mar/Apr

7.  Fentanyl and fentanyl-analog involvement in drug-related deaths.

Authors:  Zheng Dai; Marie A Abate; Gordon S Smith; James C Kraner; Allen R Mock
Journal:  Drug Alcohol Depend       Date:  2019-01-09       Impact factor: 4.492

8.  A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.

Authors:  Bahareh Ansari; Katherine M Tote; Eli S Rosenberg; Erika G Martin
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

9.  Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions.

Authors:  Yuhua Bao; Katherine Wen; Phyllis Johnson; Philip J Jeng; Zachary F Meisel; Bruce R Schackman
Journal:  Health Aff (Millwood)       Date:  2018-10       Impact factor: 6.301

10.  Prescription Drug Monitoring Program: Registration and Use by Prescribers and Pharmacists Before and After Legal Mandatory Registration, California, 2010-2017.

Authors:  Aaron B Shev; Garen J Wintemute; Magdalena Cerdá; Andrew Crawford; Susan L Stewart; Stephen G Henry
Journal:  Am J Public Health       Date:  2018-10-25       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.